Jessica Badlam, MD
Pulmonary Disease · Burlington, VTNPI 1336448778
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (51.2%), food and beverage and education — rather than concentrated in one kind of arrangement. Every reported general payment came from a single manufacturer, United Therapeutics Corporation.
Across 7 payments — averaging $91.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- United Therapeutics Corporation$642
Across 60 payments — averaging $2759.18 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- United Therapeutics Corporation$102K
- Janssen Research & Development, LLC$64K
What the payments were for
- Travel & lodging$32951%
- Food & beverage$29346%
- Education$213%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| United Therapeutics Corporation | 7 | $642 |
How this compares
$642 in reported general payments places this provider in the 55th percentile of 25 pulmonary disease providers in Vermont.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UptraviSelexipag | 14 | $430,647 |
| AdempasRiociguat | 13 | $168,314 |
| Ambrisentan | 37 | $141,776 |
| Tadalafil | 23 | $74,314 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 32 | $27,599 |
| Spiriva RespimatTiotropium Bromide | 24 | $14,143 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 44 | $13,949 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 27 | $12,630 |
| DuleraMometasone/Formoterol | 18 | $8,891 |
| SymbicortBudesonide/Formoterol Fumarate | 29 | $8,354 |
| Breo ElliptaFluticasone/Vilanterol | 15 | $7,042 |
| Sildenafil Citrate | 22 | $6,418 |
| BreynaBudesonide/Formoterol Fumarate | 11 | $2,149 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 30 | $1,367 |
| Azithromycin | 29 | $850 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Burlington
- Charles KinseyBurlington$34K
- Emily DucombBurlington$10K
- Anne DixonBurlington$4K
- Daniel WeissBurlington$3K
- Christopher YuroskoBurlington$2K
- Ena GuptaBurlington$2K
- Marta KokoszynskaBurlington$1K
- Suman MajumdarBurlington$786
- Prema MenonBurlington$18
- Garth GarrisonBurlington$18
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.